[The impact of low T3 syndrome on the prognosis of patients with newly diagnosed multiple myeloma].

This study aimed to examine the relationship between low T3 syndrome (LT3S) and the prognosis of newly diagnosed multiple myeloma (NDMM) patients. A retrospective examination of 211 NDMM patients treated at the Department of Hematology, Jiangsu Provincial People's Hospital from July 2009 to December 2020 was performed, and all patients received thyroid function testing to determine if they had LT3S. We investigated the relationship between LT3S and clinical features, as well as its impact on MM prognosis. Of the 211 patients, 119 were males, and 92 were females, with a median age of 60 (33-86) years. Patients with LT3S had significantly higher levels of β(2)-microglobulin, C-reactive protein, and blood creatinine compared to those with normal T3 levels. They also had lower levels of hemoglobin, platelets, and serum albumin, as well as more advanced ISS stages (<0.001) . Patients with LT3S had shorter progression-free survival (PFS) (16 months 30 months, =0.003) and overall survival (OS) (57 months 75 months, =0.004) than patients without LT3S. LT3S was found to be a standalone unfavorable factor in multivariate analysis, LT3S was an independent unfavorable factor in predicting both PFS (=2.114, 95% 1.271-3.516, =0.004) and OS (=2.231, 95% 1.088-4.577, =0.029) . Low T3 syndrome was an independent unfavorable prognostic predictor for NDMM.